Decentralised clinical trials are a relatively new concept in drug development. Here, digital tools are used to collect different types of data in one or more parts of the study. It can be anything from patient recruitment and consent to remote monitoring of medical parameters. But what are the benefits and challenges of this type of study?
Elham Hedayati (responsible investigator at Karolinska University Hospital), as well as Sandra Funning-Schedin (project manager for clinical studies) and Adam Szulkin (medical director) at Roche give us the answers.
Read the full text in Swedish >
Adam Szulkin, medical director at Roche. Elham Hedayati, Karolinska University Hospital. Sandra Funning-Schedin, project manager for clinical studies at Roche.